Table 2 Antibacterial activity of synthesized derivatives (1a-e)-zone of inhibition (mm,%) Jain et al. [28]
From: Synthesis and therapeutic potential of imidazole containing compounds
Compounds | Zone of inhibition | |||||
|---|---|---|---|---|---|---|
S. aureus | B. subtilis | E. coli | ||||
50(µg/mL) | 150(µg/mL) | 50(µg/mL) | 150(µg/mL) | 50(µg/mL) | 150(µg/mL) | |
1a | 5 (23.09) | 9 (42.85) | 4 (19.04) | 8 (38.09) | 7 (33.33) | 9 (42.85) |
1b | 3 (14.28) | 7 (33.33) | 4 (19.04) | 7 (33.33) | 6 (28.57) | 9 (42.85) |
1c | 5 (23.09) | 6 (28.57) | 6 (28.57) | 7 (33.33) | 5 (23.09) | 8 (38.09) |
1d | 5 (23.09) | 6 (28.57) | 6 (28.57) | 6 (28.57) | 5 (23.09) | 8 (38.09) |
1e | 4 (19.04) | 7 (33.33) | 4 (19.04) | 7 (33.33) | 5 (23.09) | 8 (38.09) |
Norfloxacin* | 21 | – | 21 | – | 21 | – |